| 1 |
Article Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. 2005
Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. · Section of Rheumatology, Nuovo Ospedale di S. Giovanni di Dio ASL 10, Via di Torregalli 3, 50143 Florence, Italy. · J Clin Rheumatol. · Pubmed #16357696 No free full text.
Abstract: We report a case of a 45-year-old man with an 8-month history of rheumatoid arthritis, who was treated with hydroxychloroquine 400 mg per day and 15 mg intramuscular methotrexate per week without reaching a good control of the disease. The patient was successfully treated with 3 mg/kg infliximab for 20 weeks. Before the last infusion, drug-induced lupus (DIL) was diagnosed based on the clinical features of fever > 37.5 degrees C, recurrence of active synovitis, myalgia, erythematosus rash, pericardial and pleural effusion, and of some laboratory findings (antinuclear antibodies 1:160 and anti double-strand DNA positive by DNA recombinant plasmid assay dsDNA). After infliximab discontinuation and the beginning of therapy with methylprednisolone, lupus symptoms resolved within 6 weeks. A new rheumatoid arthritis flare, occurring after 8 weeks, was controlled by methotrexate plus leflunomide. We also review the development of antinuclear and antidouble-strand DNA antibodies and drug-induced lupus in patients treated with anti-TNFalpha agents (infliximab, etanercept, and adalimumab).
|
| 2 |
Article [Peripheral mononuclear cells and cytokine circulating levels during adalimumab therapy in patients with rheumatoid arthritis] 2005
Benucci M, Li Gobbi F, Fossi F, Cammelli E, Manfredi M. · Sezione di Reumatologia, Dipartimento Medicina Interna, Nuovo Ospedale S.Giovanni di Dio, ASL 10, Firenze. · Recenti Prog Med. · Pubmed #16229322 No free full text.
Abstract: The aim of the study was to evaluate the composition and functional integrity of the various components of immune response in patients with rheumatoid arthritis (RA). We evaluated in 14 patients with RA with stable methotrexate therapy 12.5 mg/weekly, the number of peripheral mononuclear (PMN) cells lymphocytes, monocytes and the circulating levels of TNFalpha, IL-6 and IL-10 before and during adalimumab therapy 40 mg every other week for 6 months. No difference in baseline versus 6 months values between two treated group for PMN cells. Data about cytokines show a reduction for TNFalpha, IL-6 circulating levels and an increase for IL-10 circulating levels. Our data reveal that adalimumab doesn't reduce lymphocyte population and subsets such as CD14 or CD56 cells that have an important role against infections.
|